Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study.
Saved in:
| Title: | Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study. |
|---|---|
| Authors: | Al-Shuhaib MBS; Department of Animal Production, College of Agriculture, Al-Qasim Green University, Al-Qasim, 51013, Babil, Iraq. Electronic address: mohammed79@agre.uoqasim.edu.iq., Hashim HO; Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, 51001, Iraq. Electronic address: phar.hayder.obayes@uobabylon.edu.iq., Al-Shuhaib JMB; Babylon Directorate of Education, Ministry of Education, Babil, 51001, Iraq. Electronic address: alshuhaibjmb@gmail.com. |
| Source: | Computers in biology and medicine [Comput Biol Med] 2022 Feb; Vol. 141, pp. 105155. Date of Electronic Publication: 2021 Dec 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 1250250 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0534 (Electronic) Linking ISSN: 00104825 NLM ISO Abbreviation: Comput Biol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1879-0534 |
|---|---|
| DOI: | 10.1016/j.compbiomed.2021.105155 |
